Background
==========

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease of the joints, which often causes joint destruction, deformity and functional impairment \[[@B1]\]. Early administration of disease-modifying antirheumatic drugs (DMARDs) is crucial and the use of nonsteroidal anti-inflammatory drugs and glucocorticoids remains a fundamental aspect of medical management of RA. The discovery that the macrophage-derived proinflammatory cytokine tumour necrosis factor alpha (TNFα) plays a central role in the pathogenesis of RA \[[@B2]\] led to the introduction of anti-TNFα drugs, a new biological DMARD class. Evidence showing that anti-TNFα drugs are very effective in RA has led to a substantial change in the treatment of this disease \[[@B3]\]. Three such drugs have been commercialized since 1999: infliximab, etanercept and adalimumab. Despite this relative short history, a considerable amount of information has already been accumulated \[[@B4]-[@B6]\]. However, many questions about this new class of drugs still remain unanswered: are all available anti-TNFα drugs equally effective; does their efficacy depend upon their being administered together with methotrexate (MTX); does efficacy depend on dose; are they more effective than MTX; are all anti-TNFα drugs equally safe; what is the efficacy/safety profile? To date, no direct \"head-to-head\" comparative studies of the different anti-TNFα drugs have been published. An alternative approach to answering the foregoing questions is to perform a systematic review with metaanalysis of relevant research. A metaanalysis with emphasis on the risk of cancer and infections has been reported \[[@B7]\]. Also, a study using an indirect comparative approach to the relative efficacies of the three anti-TNFα drugs in the treatment of RA showed no differences among them \[[@B8]\].

In this paper, we conduct a systematic review of randomised controlled clinical trials of anti-TNFα drugs in RA followed by a metaanalysis of the efficacy and safety of different doses of infliximab, etanercept and adalimumab.

Methods
=======

Study selection criteria
------------------------

We carried out a search of all randomised controlled clinical trials of anti-TNFα drugs (infliximab, etanercept or adalimumab) for treating patients with RA. Patients had to satisfy the American College of Rheumatology (ACR) criteria \[[@B9]\] for diagnosis and to have active disease. Trial duration had to be at least 6 months with efficacy measured by ACR response \[[@B10]\]. Clinical trials were excluded if they either used administration routes other than recommended or included no treatment arm with recommended doses. Only information published in the trial reports was assessed.

Efficacy parameters
-------------------

We used the ACR responses ACR20, ACR50 and ACR70 (improvements of at least 20, 50 and 70%, respectively, on a series of predetermined measures) as efficacy parameters \[[@B10]\].

Safety parameters
-----------------

The following safety parameters reported in the selected trials were analyzed: number of patients suffering any adverse event, withdrawals due to adverse events, serious adverse events, infections, serious infections, infusion reactions, injection-site reactions, malignancies and overall mortality.

Search strategy
---------------

Trials were searched in scientific journals and congress conference proceedings. Information from the MEDLINE, EMBASE and Cochrane Library databases up to October 2006 was checked using a high-sensitivity strategy. The descriptors used were rheumatoid arthritis, infliximab, etanercept, adalimumab, randomised controlled trial and meta-analysis. The computerised search was completed with a manual search of reference lists from the articles retrieved and from rheumatological journal articles published in 2006 (technical details are available from the authors). There was no language restriction.

Data extraction
---------------

Two investigators (AA-R and MC) independently examined each eligible study and extracted data. Trials with information only in abstract format were excluded. Data were extracted using an ad hoc form with key items for each trial: study design, patients\' characteristics (sex, age and duration of disease evolution), patient inclusion criteria, drugs and doses used, treatment duration and ACR response and safety parameters. Special attention was paid to both inclusion criteria and clinical features of patients included in each trial, as they were deemed central aspects for assessing heterogeneity. The quality of each individual study was assessed and scored using the Jadad scale \[[@B11]\].

Statistical analysis
--------------------

For each single trial the relative risk (RR) of attaining an ACR response was obtained as a measure of the effect. Overall efficacy estimates (combined relative risk) for each anti-TNFα drug (as monotherapy or in association with MTX or another DMARD) compared to a control (placebo, MTX or another DMARD) were attained using the ACR20, ACR50, and ACR70 criteria as the main outcome variables. We used DerSimonian-Laird\'s method to estimate a random-effects model. Heterogeneity was evaluated using Cochrane\'s Q and I^2^statistics and explored via subgroup analysis. The I^2^statistic is calculated from Q and can be interpreted as the percentage variability in study results attributable to between-study differences \[[@B12]\]. The number of patients needed for experimental treatment versus control (NNT) to obtain an additional positive ACR response was also estimated \[[@B13]\].

We also used the RR to estimate the risk of adverse effects; and we estimated the number needed to harm (NNH), defined as the number of patients receiving active treatment that would harm one patient compared to controls \[[@B13]-[@B15]\].

Publication bias was assessed graphically using a funnel plot \[[@B16]\] and statistically evaluated by the regression symmetry test described by Egger et al. \[[@B17]\] and the adjusted rank correlation test proposed by Begg and Mazumdar \[[@B18]\]. We used the specific software Comprehensive Metaanalysis Version 2.0 for analysis and presentation of main results.

Results
=======

Search results
--------------

Of the 46 publications located \[[@B19]-[@B65]\], only 15 met the selection criteria and were consequently included in the metaanalysis \[[@B19]-[@B33]\]. The remaining 31 were excluded for several reasons \[[@B34]-[@B64]\] (Figure [1](#F1){ref-type="fig"}). The Maini trial \[[@B21]\] was included in the Lipsky et al. trial \[[@B19]\] and the van der Heijde et al. \[[@B28]\] and Klareskog et al. \[[@B27]\] trials were the same (TEMPO trial). We analyzed the entire set of 7087 patients recruited for the 13 trials selected: four using infliximab \[[@B19],[@B20],[@B22],[@B23]\] (2581 patients), four etanercept \[[@B24]-[@B26],[@B28]\] (1637 patients) and five adalimumab \[[@B29]-[@B33]\] (2869 patients). The methodological quality of the studies was moderate to high (3--5) except Bathon\'s trial \[[@B24]\], which had a lower Jadad score of 2 because it neither mentioned nor explained whether treatment allocation was based on a random procedure (Table [1](#T1){ref-type="table"}).

![Flow chart of the selection process for inclusion of Randomised Controlled Trials (RCT) in the overview.](1471-2474-9-52-1){#F1}

###### 

Summary of trials included in the metaanalysis

  **Trial (reference) Comparisons Jadad\'s scale (J)**                               **Groups and N of patients**   **Mean age (years)**   **Mean disease duration (years)**   **N of swollen joints**   **N of tender joints**   **CRP (mg/dl)**   **HAQ**   **Mean N of previous DMARDs**   **Previous response to MTX**   
  ---------------------------------------------------------------------------------- ------------------------------ ---------------------- ----------------------------------- ------------------------- ------------------------ ----------------- --------- ------------------------------- ------------------------------ --------------------
  Lipsky et al. (19) Infliximab+MTX vs. MTX J \[5\]                                  3 mg/Kg 8 wk \*                86                     54                                  10                        22                       32                3.9       1.8                             3.8                            Insufficient
                                                                                     3 mg/Kg 4 wk                   86                     52                                  9                         21                       31                3.5       1.7                             2.6                            
                                                                                     10 mg/Kg 8 wk                  87                     54                                  11                        23                       32                3.3       1.7                             2.5                            
                                                                                     10 mg/Kg 4 wk                  81                     52                                  12                        24                       34                4.2       1.7                             2.5                            
                                                                                     MTX                            88                     51                                  11                        21                       31                4.0       1.7                             2.5                            
                                                                                     total                          428                                                                                                                                                                                                      
  St. Clair et al. (20) Infliximab+MTX vs. MTX J \[3\]                               3 mg/Kg 8 wk \*                373                    51                                  0,8                       21                       32                2.9       1,5                             71%                            Not previously MTX
                                                                                     6 mg/Kg 8 wk                   378                    50                                  0,9                       22                       33                3.0       1,5                             68%                            
                                                                                     MTX                            298                    50                                  0,9                       22                       34                2.6       1,5                             65%                            
                                                                                     total                          1049                                                                                                                                                                      DMARDs naive                   
  Quinn et al. (22) Infliximab+MTX vs. MTX J \[3\]                                   3 mg/Kg 8 wk \*                10                     51                                  0,6                       NA                       NA                4.7       1,3                             Not previously DMARDs          Not previously MTX
                                                                                     MTX                            10                     53                                  0,5                                                                  3.7       1.3                                                            
                                                                                     total                          20                                                                                                                                                                                                       
  Westhovens et al. (23) Infliximab+MTX vs. MTX J \[4\]                              3 mg/Kg 8 wk \*                360                    53                                  7.8                       15                       22                1.6       1.5                             NA                             Insufficient
                                                                                     10 mg/Kg 8 wk \*               361                    52                                  6.3                       15                       22                1.6       1.5                                                            
                                                                                     MTX                            363                    52                                  8.4                       15                       22                1.2       1.5                                                            
                                                                                     total                          1084                                                                                                                                                                                                     
  Moreland et al. (24) Etanercept vs. placebo J \[5\]                                25 mg twice weekly \*          78                                                         11                        25                       33                4.7       1.6                             3.3                            Insufficient
                                                                                     10 mg twice weekly             76                     53                                  13                        25                       34                5.3       1.7                             3.4                            
                                                                                     placebo                        80                     53                                  12                        25                       35                4.1       1.7                             3.0                            
                                                                                     total                          234                    51                                                                                                                                                                                
  Weinblatt et al. (25) Etanercept+MTX vs. MTX J \[3\]                               25 mg twice weekly \*          59                                                         13                        20                       28                2.2       1.5                             2.7                            Insufficient
                                                                                     MTX                            30                                                         13                        17                       28                2.6       1.5                             2.8                            
                                                                                     total                          89                     48                                                                                                                                                                                
                                                                                                                                           53                                                                                                                                                                                
  Bathon et al. (26) Etanercept vs. MTX J \[2\]                                      25 mg twice weekly \*          207                    51                                  1                         24                       31                3.3       NA                              0.5                            Not previously MTX
                                                                                     10 mg twice weekly             208                    50                                  0.9                       24                       31                4.4                                       0.5                            
                                                                                     MTX                            217                    49                                  1                         24                       30                3.7                                       0.6                            
                                                                                     total                          632                                                                                                                                                                                                      
  van der Heijde et al. (28) (TEMPO) Etanercept+MTX vs. MTX vs. Etanercept J \[4\]   25 mg twice weekly +MTX \*     231                                                        7                         22                       34                2.9       NA                              2.3                            
                                                                                     25 mg twice weekly \*          223                                                        6                         23                       35                2.2                                       2.3                            
                                                                                     MTX                            228                    52                                  7                         22                       33                3.5                                       2.3                            
                                                                                     total                          682                    53                                                                                                                                                                                
                                                                                                                                           53                                                                                                                                                                                
  Weinblatt et al. (29) (ARMADA) Adalimumab+MT X vs. MTX J \[3\]                     40 mg/2 wk \*                  67                     57                                  12                        17                       28                2.1       1.5                             2.9                            Insufficient
                                                                                     20 mg/2 wk                     69                     53                                  13                        17                       28                2.8       1.5                             3.0                            
                                                                                     80 mg/2 wk                     73                     55                                  12                        17                       30                2.8       1.5                             3.1                            
                                                                                     MTX                            62                     56                                  11                        16                       28                3.1       1.6                             3.0                            
                                                                                     total                          271                                                                                                                                                                                                      
  van de Putte et al. (30) Adalimumab vs. Placebo J \[5\]                            40 mg/2 wk \*                  113                    52                                  10                        20                       33                5.2       1.8                             3.8                            Insufficient
                                                                                     20 mg/2 wk                     106                    53                                  9                         19                       33                5.2       1.8                             3.7                            
                                                                                     20 mg/wk                       112                    54                                  11                        19                       35                4.7       1.8                             3.6                            
                                                                                     40 mg/wk                       103                    51                                  11                        19                       33                4.9       1.8                             3.8                            
                                                                                     Placebo                        110                    53                                  11                        19                       35                5.7       1.8                             3.6                            
                                                                                     total                          544                                                                                                                                                                                                      
  Furst et al. (31) (STAR) Adalimumab+ DMARD vs. DMARD J \[3\]                       40 mg/2 wk \*                  318                                                        9                         20                       27                1.5       1.3                             57--60%                        Insufficient
                                                                                     DMARD                          318                                                        11                        21                       27                1.5       1.4                             2 or plus                      
                                                                                     total                          636                    55                                                                                                                                                                                
                                                                                                                                           55                                                                                                                                                                                
  Keystone et al. (32) Adalimumab+MT X vs. MTX J \[3\]                               40 mg/2 wk \*                  207                    56                                  11                        19                       27                1.8       1.4                             2.4                            Insufficient
                                                                                     20 mg/wk                       212                    57                                  11                        19                       27                1.4       1.4                             2.4                            
                                                                                     MTX                            200                    56                                  10                        19                       28                1.8       1.4                             2.4                            
                                                                                     total                          619                                                                                                                                                                                                      
  Breedveld et al. (33) (PREMIER) Adalimumab+MT X vs. MTX vs. Adalimumab J \[4\]     40 mg/2 wk + MTX \*            268                    52                                  0,7                       21                       31                NA        1.5                             NA                             Not previously MTX
                                                                                     40 mg/2 wk                     274                    52                                  0,7                       22                       32                          1.6                                                            
                                                                                     MTX                            257                    52                                  0,8                       22                       32                          1.5                                                            
                                                                                     total                          799                                                                                                                                                                                                      

\*groups receiving doses currently recommended

NA: not available

CRP: C-reactive protein

HAQ: health assessment questionnaire

Trial characteristics
---------------------

Table [1](#T1){ref-type="table"} shows the major characteristic of the 13 trials included in the review. Information on efficacy at 6, 12 and 24 months and the previously-described safety parameters were analyzed.

There are four infliximab trials: Lipsky et al. \[[@B19]\], St. Clair et al. \[[@B20]\], Quinn et al. \[[@B22]\] and Westhovens et al. \[[@B23]\]. Lipsky et al. \[[@B19]\] used a randomised double blind 12-month trial (with information at 6 and 12 months). Four hundred and twenty-eight patients insufficiently responsive to MTX were included. Patients were randomized to 5 arms, four with infliximab plus MTX and a control arm with MTX alone. The purpose of this study was to demonstrate that infliximab was capable of inhibiting the progression of structural joint damage. It was a continuation of the Maini et al. trial \[[@B21]\]. The St. Clair et al. trial \[[@B20]\] compared infliximab plus MTX with MTX alone. The 1049 patients included in this trial had a recent onset of RA (disease duration in the range 3 months to 3 years). They had not previously received MTX, and MTX was administered following a rapid dose-increasing schedule during the trial (7.5 mg/wk at week 0, increasing by 2.5 mg per week to 15 mg/wk at week 5 and 20 mg/wk at week 8). The trial lasted 12 months. The Quinn et al. \[[@B22]\] trial was a small study comparing infliximab plus MTX with MTX alone in recent-onset RA patients. Westhovens et al. \[[@B23]\] conducted a 12-month trial but the double blind efficacy data were analyzed at week 22.

Four trials testing etanercept were analysed. Moreland et al. \[[@B24]\] compared etanercept in monotherapy with a placebo. Weinblatt et al. \[[@B25]\] compared etanercept plus MTX with MTX alone. In the Bathon et al. trial \[[@B26]\], etanercept in monotherapy was compared with MTX. Finally, the TEMPO trial (Trial of Etanercept and Methotrexate with radiographic Patient Outcomes) \[[@B28]\] compared etanercept in monotherapy with both MTX and a combination of etanercept plus MTX. Moreland et al. included 234 patients \[[@B24]\] in a 6 month-trial comparing the response to etanercept with placebo. Patients had previously shown an inadequate response to at least 1 DMARD (80% to MTX). They had received an average of three DMARDs and were therefore defined as refractory to standard treatments. Weinblatt et al. \[[@B25]\] included 89 patients with inadequate responses to MTX. The duration of the trial was 6 months. Bathon et al. \[[@B26]\] recruited 632 patients with recent RA onset (less than 3 years\' duration). Patients ought not to have been treated with MTX previously. The trial lasted 1 year (with information at 6 and 12 months) and MTX was administered in a rapid dose-increasing schedule (initial dose 7.5 mg/wk, increased to 15 mg/wk at week 4 and 20 mg/wk at week 8). The TEMPO trial \[[@B28]\] included 682 patients with RA and insufficient DMARD responses. Around 40% had previously received MTX (but patients previously treated with MTX had neither discontinued it owing to toxicity nor been treated with MTX within 6 months of enrolment). The trial lasted 2 years. MTX was administered in a rapid dose-increasing schedule to 20 mg/wk in 8 weeks. The main goal of this study was to demonstrate that etanercept was capable of inhibiting the progression of structural joint damage.

There were five adalimumab trials. The ARMADA trial (The Anti-tumour necrosis factor Research study programme of the Monoclonal Antibody adalimumab in rheumatoiD Arthritis) \[[@B29]\] compared the efficacy of 6 months\' treatment with adalimumab plus MTX with MTX alone in 271 patients with insufficient responses to MTX and at least one other DMARD. The van de Putte et al. trial \[[@B30]\] compared the efficacy of adalimumab with a placebo after 6 months treatment. All 544 patients included had inadequate responses to MTX and 3 other DMARDs. The basic purpose of the STAR trial (Safety Trial of Adalimumab in Rheumatoid arthritis) \[[@B31]\] was to study adalimumab safety. It recruited 636 patients with inadequate responses to any DMARD who were subsequently randomised either to continue with their current DMARD alone or to use a combination of the DMARD with adalimumab for 6 months. The Keystone et al. \[[@B32]\] trial had a similar design to ARMADA with a 12-month duration (information at 6 and 12 months), comparing adalimumab plus MTX with MTX alone in 619 patients. The basic purpose of this study was to demonstrate that adalimumab could inhibit the progression of structural joint damage. The PREMIER trial \[[@B33]\] compared the efficacies of adalimumab, adalimumab plus MTX and MTX alone in 799 patients at 24 months without previous treatment with MTX.

For each selected trial we extracted data on major features of the study design and characteristics of the patients included (Table [1](#T1){ref-type="table"}). Weekly doses of MTX administered to the patients during the trials averaged 16 mg, except for the St. Clair et al. \[[@B20]\], TEMPO \[[@B28]\]. Bathon et al. \[[@B26]\] and PREMIER trials \[[@B33]\], in which MTX was administered in a rapid dose-increasing schedule to 20 mg/wk. The clinical profile of RA also varied across trials. Patients had a long history of RA (around 10 years) in most trials but a shorter evolution time in four of them: under 3 years in the St. Clair et al. \[[@B20]\], Bathon et al. \[[@B26]\] and Quinn et al. \[[@B22]\] and PREMIER \[[@B33]\] trials and around 6 years in the TEMPO \[[@B28]\] study. Therapeutic use of MTX prior to enrolment in the trial was also considered, because failure of or inadequate response to prior MTX administration entails a low response rate in the control group.

Metaanalysis results
--------------------

### Efficacy of anti-TNFα drugs. Global analysis

We studied the efficacies of the anti-TNFα drugs in the 13 trials included \[[@B19]-[@B33]\] (Table [2](#T2){ref-type="table"}). Global comparison of the ACR20 efficacy of any dose of any anti-TNFα drug with any control treatment showed a combined effect of 1.81 (95% CI 1.43--2.29) with an NNT of 6 (5--7). The combined effects were 1.89 (1.30--2.75) for adalimumab trials, 1.71 (1.11--2.63) for etanercept trials and 1.82 (1.19--2.77) for infliximab trials. Further analyses using ACR50 and ACR70 efficacies showed very similar results (Figure [2](#F2){ref-type="fig"}).

###### 

Efficacy of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses

  **Trial (reference) Comparisons Duration of trial in months**                       **Groups**                     **N of patients**   **6 month ACR20**   **6 month ACR50**   **6 month ACR70**   **12 month ACR20**   **12 month ACR50**   **12 month ACR70**   **24 month ACR20**   **24 month ACR50**   **24 month ACR70**
  ----------------------------------------------------------------------------------- ------------------------------ ------------------- ------------------- ------------------- ------------------- -------------------- -------------------- -------------------- -------------------- -------------------- --------------------
  Lipsky et al. (19) Infliximab+MTX vs. MTX 12 months                                 3 mg/Kg 8 wk +MTX\*            86                                      22/86               7/86                36/86                18/86                9/86                                                           
                                                                                      3 mg/Kg 4 wk +MTX              86                  43/86               25/86               9/86                41/86                29/86                31/86                                                          
                                                                                      10 mg/Kg 8 wk +MTX             87                  43/86               27/87               15/87               51/87                34/87                22/87                                                          
                                                                                      10 mg/Kg 4 wk +MTX             81                  45/87               21/81               9/81                48/81                31/81                15/81                                                          
                                                                                      Total Infliximab               340                 47/81               95/340              40/340              176/340              112/340              77/340                                                         
                                                                                      MTX                            88                  178/340             4/88                0/88                15/88                7/88                 2/88                                                           
                                                                                      Total                          428                 18/88                                                                                                                                                                
  *St. Clair et al. (20)*Infliximab+MTX vs. MTX 12 months                             3 mg/Kg 8 wk +MTX\*            373                                     NA                  NA                  231/373              171/373              123/373                                                        
                                                                                      6 mg/Kg 8 wk +MTX              378                                                                             249/378              189/378              140/378                                                        
                                                                                      Total Infliximab               751                 NA                                                          480/751              360/751              263/751                                                        
                                                                                      MTX                            298                                                                             161/298              95/298               62/298                                                         
                                                                                      Total                          1049                                                                                                                                                                                     
  Quinn et al. (22) Infliximab+MTX vs. MTX 12 months                                  3 mg/Kg 8 wk +MTX\*            10                                                                              8/10                 8/10                 7/10                                                           
                                                                                      MTX                            10                  NA                  NA                  NA                  6/10                 4/10                 3/10                                                           
                                                                                      Total                          20                                                                                                                                                                                       
  Westhovens et al. (23) Infliximab+MTX vs. MTX 6 months                              3 mg/Kg 8 wk +MTX\*            360                                     110/360             48/360                                                                                                                       
                                                                                      10 mg/Kg 8 wk +MTX             361                 199/360             119/361             54/341                                                                                                                       
                                                                                      Total Infliximab               721                 205/361             229/721             102/721                                                                                                                      
                                                                                      MTX                            363                 404/721             33/363              16/363                                                                                                                       
                                                                                      Total                          1084                87/363                                                                                                                                                               
  oreland et al. (24) Etanercept vs. placebo 6 months                                 25 mg 2 twice weekly \*        78                                      31/78               11/78                                                                                                                        
                                                                                      10 mg 2 twice weekly           76                  46/78               18/76               7/76                                                                                                                         
                                                                                      Total Etanercept               154                 37/76               49/154              18/154                                                                                                                       
                                                                                      Placebo                        80                  83/154              4/80                1/80                                                                                                                         
                                                                                      Total                          234                 9/80                                                                                                                                                                 
  Weinblatt et al. (25) Etanercept+MTX vs. MTX 6 months                               25 mg 2 +MTX \*                59                  42/59               23/59               9/59                                                                                                                         
                                                                                      MTX                            30                  8/30                1/30                0/30                                                                                                                         
                                                                                      Total                          89                                                                                                                                                                                       
  Bathon et al. (26) \*\* *Etanercept vs. MTX*12 months                               25 mg 2 twice weekly \*        207                 147/207             NA                  NA                  149/207              101/207              52/207                                                         
                                                                                      10 mg 2 twice weekly           208                 NA                  NA                  NA                  NA                   NA                   NA                                                             
                                                                                      Total Etanercept               415                 56/217              NA                  NA                  141/217              93/217               47/217                                                         
                                                                                      MTX                            217                                                                                                                                                                                      
                                                                                      Total                          632                                                                                                                                                                                      
  van der Heijde et al. (28) (TEMPO) Etanercept+MTX vs. etanercept vs MTX 24 months   25 mg 2 twice weekly +MTX \*   231                 NA                  NA                  NA                  196/231              159/231              99/231               199/231              164/231              113/231
                                                                                      25 mg 2 twice weekly\*         223                                                                             169/223              107/223              54/223               167/223              120/223              60/223
                                                                                      Total Etanercept               454                                                                             365/454              266/454              153/454              386/454              284/454              173/454
                                                                                      MTX                            228                                                                             171/228              98/228               43/228               162/228              96/228               4/228
                                                                                      Total                          682                                                                                                                                                                                      
  Weinblatt et al. (29) ARMADA) dalimumab+MTX vs. MTX 6 months                        40 mg/2 s+MTX\*                67                  45/67               37/67               18/67                                                                                                                        
                                                                                      20 mg/2 s+MTX                  69                  33/69               22/69               7/69                                                                                                                         
                                                                                      80 mg/2 s+MTX                  73                  48/73               31/73               14/73                                                                                                                        
                                                                                      Total Adalimumab               209                 126/209             90/209              39/209                                                                                                                       
                                                                                      MTX                            62                  9/62                5/62                3/62                                                                                                                         
                                                                                      Total                          271                                                                                                                                                                                      
  van de Putte et al. (30) Adalimumab vs. Placebo 6 months                            40 mg/2 wk \*                  113                                     25/113              14/113                                                                                                                       
                                                                                      20 mg/2 wk                     106                 52/113              20/106              9/106                                                                                                                        
                                                                                      20 mg/wk                       112                 38/106              23/112              11/112                                                                                                                       
                                                                                      40 mg/wk                       103                 44/112              36/103              19/103                                                                                                                       
                                                                                      Total Adalimumab               434                 55/103              104/434             53/434                                                                                                                       
                                                                                      Placebo                        110                 189/434             9/110               2/110                                                                                                                        
                                                                                      Total                          544                 21/110                                                                                                                                                               
  Furst et al. (31) (STAR) Adalimumab+DAMAR D vs. DAMARD 6 months                     40 mg/2 wk \*                  318                                     93/318              47/318                                                                                                                       
                                                                                      DMARD                          318                 169/318             35/318              10/318                                                                                                                       
                                                                                      Total                          636                 111/318                                                                                                                                                              
  Keystone et al. (32) Adalimumab+MTX vs. MTX 12 months                               40 mg/2 wk +MTX\*              207                 131/207             80/207              43/207              122/207              86/207               48/207                                                         
                                                                                      20 mg/wk +MTX                  212                 129/212             87/212              36/212              116/212              80/212               44/212                                                         
                                                                                      Total Adalimumab               419                 260/419             167/419             79/419              238/419              166/419              92/419                                                         
                                                                                      MTX                            200                 59/200              19/200              5/200               48/200               19/200               9/200                                                          
                                                                                      Total                          619                                                                                                                                                                                      
  Breedveld et al. (33) (PREMIER) Adalimumab+MTX vs. adalimumab vs MTX 24 months      40 mg/2 wk+MTX\*               268                 NA                  *NA*                NA                  196/268              166/268              123/268              185/268              158/268              126/268
                                                                                      40 mg/2 wk \*                  274                                                                             148/274              112/274              71/274               134/274              101/274              77/274
                                                                                      Total Adalimumab               542                                                                             344/542              278/542              194/542              319/542              259/542              203/542
                                                                                      MTX                            257                                                                             162/257              118/257              72/257               144/257              111/257              72/257

\* groups receiving doses currently recommended

NA: not available

![**Efficacy of all doses of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses.**Effect refers to the risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. \'Lower\' and \'upper\' represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.](1471-2474-9-52-2){#F2}

Analysis of this set of 13 trials provided evidence of relevant and statistically significant heterogeneity (Q = 157.7; p \< 0.001; I^2^92%). Although the limited number of trials reduced the discriminatory power of the funnel plot, it suggested a certain degree of asymmetry (Figure [3](#F3){ref-type="fig"}), which was statistically confirmed by both the Begg and Mazumdar adjusted rank correlation test (p = 0.033) and Egger\'s regression asymmetry test (p = 0.001).

![**Funnel plot of selected studies.** The x-axis shows effect estimates (RR) on a logarithmic scale (any effect estimate greater than zero therefore indicates better results for experimental treatment) while the y-axis measures the precision of each study (as the inverse of the standard error of the effect estimate measured on a logarithmic scale).](1471-2474-9-52-3){#F3}

Bearing all these aspects in mind, we focused on the analysis of subgroups that appeared more homogeneous on both clinical and trial design grounds: previous exposure and response to DMARDs, mainly MTX, dose of anti-TNFα drug administered and control treatment selected (active or placebo, single or combined). The effects (RR) obtained with different doses of anti-TNFα appear in Table [3](#T3){ref-type="table"}. The distinct NNTs and the analysis of heterogeneity appear in Table [4](#T4){ref-type="table"}. Evidently the specific subgroups of trials characterised by these features are much less heterogeneous on analysis.

###### 

Effects (RR and NNT (95% CI)) obtained with different doses of anti-TNFα drugs

                       **All doses of anti-TNFα drugs vs. control 4618 vs. 2261\***   **Recommended doses of anti-TNFα drugs vs. control 2874 vs. 2260\*\***   **High-doses drugs vs. control 1169 vs. 921\*\*\* of anti-TNFα**   **Low-doses of anti-TNFα drugs vs. control 251 vs. 252\*\*\*\***                                                                                                                            
  ------------ ------- -------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------------ --------------------------------------------------- ----------------- -------------------------------------------------- -------------
  Anti-TNFα    ACR     RR (CI 95%)                                                    NNT                                                                      RR (CI 95%)                                                        NNT                                                                RR (CI 95%)                                         NNT               RR (CI 95%)                                        NNT
                                                                                                                                                                                                                                                                                                                                                                                                                              
  Adalimumab   ACR20   1.9 (1.3--2.8)                                                 6 (5--7)                                                                 2.0 (1.3--2.9)                                                     5 (4--6)                                                           3.5 (1.6--7.3)                                      3 (2--4)          2.4 (1.4--4.1)                                     5 (4--8)
               ACR50   2.7 (1.6--4.4)                                                 6 (5--7)                                                                 2.8 (1.6--4.7)                                                     5 (5--6)                                                           4.7 (1.9--12.0)                                     4 (3--5)          2.9 (1.6--5.1)                                     7 (5--13)
               ACR70   3.3 (1.8--6.3)                                                 9 (7--11)                                                                3.5 (1.9--6.7)                                                     7 (6--8)                                                           6.1 (1.8--20.8)                                     7 (5--11)         3.0 (1.1--7.9)                                     17 (9--77)
  Etanercept   ACR20   1.7 (1.1--2.6)                                                 7(5--10)                                                                 1.7 (1.1--2.7)                                                     6 (5--8)                                                           There are no trials with high doses of Etanercept   4.3 (1.9--10.1)   3 (2--5)                                           
               ACR50   2.1 (1.1--3.9)                                                 6 (5--9)                                                                 2.2 (1.1--4.3)                                                     6 (4--7)                                                                                                                                 4.7 (1.7--13.4)                                    6 (4--13)
               ACR70   2.0 (0.9--4.4)                                                 NS                                                                       2.1 (0.9--4.5)                                                     NS                                                                                                                                       7.4 (0.9--58.5)                                    NS
  Infliximab   ACR20   1.8 (1.2--2.8)                                                 5 (4--6)                                                                 1.7 (1.1--2.6)                                                     5 (4--6)                                                           2.0 (1.2--3.6)                                      5 (4--5)          There are no trials with low doses of Infliximab   
               ACR50   2.6 (1.5--4.7)                                                 5 (5--6)                                                                 2.2 (1.2--4.1)                                                     6 (5--7)                                                           2.8 (1.5--5.5)                                      5 (4--6)                                                             
               ACR70   2.9 (1.4--5.8)                                                 8 (6--10)                                                                2.4 (1.2--5.0)                                                     9 (7--13)                                                          3.3 (1.5--7.2)                                      7 (6--7)                                                             
  Overall      ACR20   1.8 (1.4--2.3)                                                 6 (5--7)                                                                 1.8 (1.4--2.3)                                                     5 (5--6)                                                           2.5 (1.5--4.2)                                      4 (5--4)          2.9 (1.7--5.1)                                     4 (3--6)
               ACR50   2.5 (1.8--3.4)                                                 6 (5--6)                                                                 2.4 (1.7--3.4)                                                     5 (5--6)                                                           3.4 (2.0--5.8)                                      5 (4--5)          3.2 (2.0--5.3)                                     6 (5--10)
               ACR70   2.8 (1.9--4.2)                                                 8 (7--9)                                                                 2.7 (1.8--4.1)                                                     7 (7--9)                                                           3.9 (2.0--7.6)                                      7 (6--8)          3.5 (1.4--8.6)                                     15 (10--38)

NNT: number of patients needed to be treated

RR (95%CI): relative risk (95% confidence limits)

NS: non-significant results

\*4618 patients being treated with anti-TNFα (except 208 patients Bathon\'s trial being treated with 10 mg of etanercept twice a week) vs 2261 patients of the control groups

\*\*2874 patients with recommended doses of anti-TNFα drugs (Infliximab 3 mg/Kg/8 week; etanercept 25 mg twice a week; adalimumab 40 mg every 2 weeks) vs 2260 patients of the control groups

\*\*\*1169 patients with high-doses of anti-TNFα drugs (infliximab 3 mg/Kg 4 week, 6 mg/Kg 8 week, 10 mg/Kg 8 week and 10 mg/Kg 4 week; adalimumab 40 mg/week, 80 mg/2 week) vs 921 patients of the control groups

\*\*\*\*251 patients with low-doses of anti-TNFα drugs (etanercept 10 mg twice weekly; adalimumab 20 mg/2 week) vs 252 patients of the control groups

###### 

Efficacy and heterogeneity

  **Comparisons (Anti-TNFα vs. control)\*\*\***                                                                                 **ACR response**   **Anti-TNFα Events/Total**   **Control Events/Total**   **RR (CI 95%)**   **NNT**       **Q**     **I**^2^%
  ----------------------------------------------------------------------------------------------------------------------------- ------------------ ---------------------------- -------------------------- ----------------- ------------- --------- -----------
  All doses of anti-TNFα drugs vs. control (4618 vs. 2261)                                                                      ACR20              2709/4618                    941/2261                   1.8 (1.4--2.3)    6 (5--7)      157.7\*   92
                                                                                                                                ACR50              1879/4618                    519/2261                   2.5 (1.8--3.4)    6 (5--6)      109.8\*   89
                                                                                                                                ACR70              1106/4618                                               2.8 (1.9--4.1)    8 (7--9)      52.4\*    77
  Recommended doses of anti-TNFα drugs vs. control (2874 vs. 2260)                                                              ACR20              1808/2874                    949/2261                   1.8 (1.4--2.3)    5 (5--6)      149.5\*   92
                                                                                                                                ACR50              1247/2874                    519/2261                   2.4 (1.7--3.4)    5 (5--6)      102.9\*   88
                                                                                                                                ACR70              733/2874                     270/2261                   2.7 (1.8--4.1)    7 (7--9)      49.2\*    76
  High-doses of anti-TNFα drugs vs. control (1169 vs. 921)                                                                      ACR20              697/1169                     293/921                    2.5 (1.5--4.2)    4 (4--5)      57.2\*    93
                                                                                                                                ACR50              469/1169                     149/921                    3.4 (2.0--5.8)    5 (4--5)      30.5\*    87
                                                                                                                                ACR70              295/1169                     85/921                     3.9 (2.0--7.6)    7 (6--8)      16.6\*    76
  *Low-doses of anti-TNFα drugs vs. control (251 vs. 252)*                                                                      ACR20              108/251                      39/252                     2.9 (1.7--5.1)    4 (3--6)      4.9       59
                                                                                                                                ACR50              60/251                       18/252                     3.2 (2.0--5.3)    6 (5--10)     1.5       0
                                                                                                                                ACR70              23/251                       6/252                      3.5 (1.4--8.6)    15 (10--38)   1.2       0
  Anti-TNFα drugs vs. control in patients with No insufficient response to MTX (1964 vs. 1010)                                  ACR20              1346/1964                    641/1010                   1.1 (0.9--1.3)    NS            2.4       9
                                                                                                                                ACR50              1013/1964                    408/1010                   1.3 (1.1--1.5)    9 (7--13)     8.8       55
                                                                                                                                ACR70              669/1964                     227/1010                   1.5 (1.3--1.7)    12 (9--19)    7.0       43
  Anti-TNFα drugs vs. control in patients with insufficient response to MTX (2654 vs. 1251)                                     ACR20              1427/2654                    308/1251                   2.3 (2.0--2.7)    4 (3--5)      28.2\*    75
                                                                                                                                ACR50              866/2654                     113/1251                   3.6 (2.9--4.4)    5 (4--5)      7.2       3
                                                                                                                                ACR70              437/2654                     43/1251                    4.4 (3.2--6.0)    7 (6--8)      4.2       0
  Anti-TNFα drugs at recommended doses plus MTX vs. MTX alone in patients with insufficient response to MTX (779 vs. 743)       ACR20              444/779                      167/743                    2.6 (2.1--3.3)    3 (3--4)      4.3       7
                                                                                                                                ACR50              274/779                      65/743                     4.1 (2.6--6.6)    4 (4--5)      4.6       13
                                                                                                                                ACR70              132/779                      30/743                     4.1 (2.4--7.1)    8 (7--11)     2.5       0
  Anti-TNFα drugs versus placebo at recommended doses (191 vs. 190)                                                             ACR20              98/191                       30/190                     3.4 (1.6--7.3)    3 (3--4)      3.8\*     74
                                                                                                                                ACR50              56/191                       13/190                     4.4 (1.5--12.5)   5 (4--7)      2.9       66
                                                                                                                                ACR70              25/191                       3/190                      8.1 (2.5--26.4)   9 (7--16)     0.1       0
  Anti-TNFα drugs at recommended doses plus MTX versus MTX alone in patients with no previous resistance to MTX (882 vs. 793)   ACR20              631/882                      500/793                    1.2 (1.1--1.2)    10 (7--16)    0.4       0
                                                                                                                                ACR50              504/882                      315/793                    1.6 (1.4--1.7)    6 (5--8)      1.1       0
                                                                                                                                ACR70              352/882                      180/793                    1.8 (1.5--2.1)    6 (5--8)      3.9       23
  Anti-TNFα drugs versus MTX at recommended doses (704 vs. 702)                                                                 ACR20              466/704                      474/702                    1.0 (0.9--1.1)    NS            6.9\*     71
                                                                                                                                ACR50              320/704                      309/702                    1.0 (0.9--1.2)    NS            3.6       45
                                                                                                                                ACR70              177/704                      162/702                    1.1 (0.9--1.3)    NS            2.2       11

RR (95%CI): relative risk (95% confidence limits)

NNT: number of patients needed to be treated

Q: Cochrane\'s Q

I^2^: percentage of variability in study results attributable to between-study differences

\* statistical heterogeneity

NS: non-significant results

\*\*\* number of patients being treated with anti-TNFα versus number of patients in the control groups

### Efficacy of anti-TNFα drugs depending on prior exposure and response to MTX

The efficacy results (Figure [4](#F4){ref-type="fig"}) show that this factor leads to rather different estimates and should be taken into account. When the effect of an anti-TNFα drug is assessed in patients who have received no previous MTX treatment, the relative ACR20 effect is small and only marginally statistically significant: 1.10 (0.96--1.26). On the other hand, when the anti-TNFα drug effect is analysed in patients with previously insufficient responses to MTX, the relative effect is substantially larger (2.32 \[1.99--2.72\]) and both clinically relevant and statistically significant \[NNT of 4 (3--5)\]. Similar results are seen with the ACR50 and ACR70 responses, though here the effect in patients naïve to MTX is statistically significant compared to control arms.

![**Efficacy of anti-TNFα drugs depending on an insufficient response to MTX prior to trial commencement.** Effect refers to risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. \'Lower\' and \'Upper\' represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.](1471-2474-9-52-4){#F4}

### Analysis of the effect of different doses of anti-TNFα drugs

We analysed the efficacy of anti-TNFα drug administration in three separate groups: currently recommended doses (infliximab 3 mg/Kg/8 week; etanercept 25 mg twice a week; adalimumab 40 mg every 2 weeks); high doses (infliximab 3 mg/Kg/4 week, 6 mg/Kg/8 week, 10 mg/Kg/8 week and 10 mg/Kg/4 week; adalimumab 40 mg/week, 80 mg/2 week); and low doses (etanercept 10 mg 10 mg twice weekly; adalimumab 20 mg/2 week). No patient receiving infliximab was prescribed lower than recommended doses, and no patient treated with etanercept received higher than recommended doses. The group given adalimumab 20 mg/week was not included as this dose schedule can be considered neither above nor below the currently recommended regime. The combined and individual effects of the adalimumab, etanercept and infliximab trials at any dose or in subgroups based on the dose level are shown in Table [3](#T3){ref-type="table"}. A statistically significantly beneficial effect is apparent with recommended, higher or lower doses in all the comparisons made, except for the ACR70 response to etanercept. Accordingly, the NNTs are very similar for all anti-TNFα drugs.

### Analysis of the effect of anti-TNFα drugs at recommended doses

Five trials \[[@B19],[@B23],[@B25],[@B29],[@B32]\] compared the effects of anti-TNFα drugs plus MTX with MTX alone in patients with insufficient responses to MTX. A beneficial combined effect in the ACR20 response is shown: RR 2.60 (2.05--3.31) with an NNT of 4 (3--4). Analyses using the ACR50 and ACR70 responses showed very similar results (Figure [5](#F5){ref-type="fig"}). There was no evidence of statistical heterogeneity among the different drug classes (Table [4](#T4){ref-type="table"}).

![**Efficacy of anti-TNFα drugs at recommended doses in combination with MTX compared with MTX alone in patients with insufficient responses to MTX.** Effect refers to risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. \'Lower\' and \'Upper\' represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.](1471-2474-9-52-5){#F5}

Only two trials \[[@B24],[@B30]\] assessed the effect of anti-TNFα drugs versus placebo, showing a combined positive effect on the ACR20 response with an RR of 3.42 (1.60--7.30) and an NNT of 3 (3--4). Although there was a statistically significant heterogeneity of effects according to which drug had been used (Q = 3.8; p = 0.049; I^2^= 74) with etanercept apparently more effective than adalimumab (Figure [6](#F6){ref-type="fig"}), it should be emphasized that there was no direct head to head comparison among them. There was no statistical evidence of heterogeneity in either the ACR50 or the ACR70 response, but the estimates of the effect varied widely between the two drugs, with a pattern similar to that obtained with the ACR20 outcome and based on a rather small number of patients.

![**Efficacy of anti-TNFα drugs versus placebo at recommended doses.** Effect refers to risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. \'Lower\' and \'Upper\' represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.](1471-2474-9-52-6){#F6}

Four trials \[[@B20],[@B22],[@B28],[@B33]\] compared the effect of anti-TNFα drug plus MTX with MTX alone in patients with no previous resistance to MTX. This analysis showed a small but significant combined effect on the ACR20 response of 1.15 (1.07--1.22) with an NNT of 10 (7--16) (Figure [7](#F7){ref-type="fig"}). The ACR50 showed a combined effect of 1.56 (1.41--1.72) whereas that effect was 1.77 (1.52--2.05) for ACR70. No statistically significant heterogeneity was present for any of these outcomes.

![**Efficacy of anti-TNFα drugs plus MTX compared to MTX alone in patients with no previous resistance to MTX (at the recommended doses).** Effect refers to risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. \'Lower\' and \'Upper\' represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.](1471-2474-9-52-7){#F7}

Three trials compared efficacies of anti-TNFα drugs with MTX alone as control \[[@B26],[@B28],[@B33]\]. The ACR20 combined effect showed no significant difference among the arms, with RR = 1.00 (0.92--1.08). Results were similar for the ACR50 and ACR70 responses (Figure [8](#F8){ref-type="fig"}). The heterogeneity was marginally significant for ACR20 and significant for ACR50 (Table [4](#T4){ref-type="table"}).

![**Efficacy of anti-TNFα drugs compared to MTX at recommended doses.** Effect refers to risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. \'Lower\' and \'Upper\' represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.](1471-2474-9-52-8){#F8}

Safety analysis
---------------

An overview of the adverse events reported in the selected trials is displayed in Table [5](#T5){ref-type="table"}. The number of withdrawals due to adverse events according to treatment arm was reported in all trials. Information on the incidence of serious infections, malignancies and mortality is also provided, specifying whether patients were in the experimental or control arms, but information about the specific treatment group of the patient was sometimes lacking. Other important safety information (overall number of adverse events, severe adverse events, total number of infections, infusion reactions and injection-site reactions) was provided much less consistently.

###### 

Number of patients who presented adverse effects in trials with anti TNFα drugs

  **Trial (reference) Anti-TNFα drug**            **Groups**    **N of patients**   **Withdrawn adverse event**   **Total adverse events**   **Serious adverse events**   **Infections**   **Serious infections**   **Infusion reactions**   **Injection- site reactions**   **Malignancies**   **Mortality**
  ----------------------------------------------- ------------- ------------------- ----------------------------- -------------------------- ---------------------------- ---------------- ------------------------ ------------------------ ------------------------------- ------------------ ---------------
  Lipsky et al. (19) Infliximab                   3 mg/Kg 8     86                  5                             \_                         \_                           \_               \_                                                                                \_                 \_
                                                  wk +MTX       86                  9                             \_                         \_                           \_               \_                                                                                \_                 \_
                                                  3 mg/Kg 4     87                  4                             \_                         \_                           \_               \_                                                                                \_                 \_
                                                  wk +MTX       81                  8                             \_                         \_                           \_               \_                                                                                \_                 \_
                                                  10 mg/Kg 8    340                 26                            323                        58                           244              22                                                                                5                  5
                                                  wk +MTX       88                  7                             83                         18                           53               7                        NA                                                       0                  3
                                                  10 mg/Kg 4                                                                                                                                                                                                                                    
                                                  wk +MTX                                                                                                                                                                                                                                       
                                                  Total                                                                                                                                                                                                                                         
                                                  Infliximab                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  St. Clair et al. (20) Infliximab                3 mg/Kg 8     373                 34                                                       \_                           \_               21                       \_                                                       0                  1
                                                  wk +MTX       378                 35                                                       \_                           \_               19                       \_                                                       4                  1
                                                  6 mg/Kg 8     751                 69                                                       103                          414              40                       135                                                      4                  2
                                                  wk +MTX       298                 9                             NA                         32                           141              6                        20                                                       0                  2
                                                  Total                                                                                                                                                                                                                                         
                                                  Infliximab                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  Quinn et al. (22) Infliximab                    3 mg/Kg 8     10                  1                                                        1                                             0                        1                                                        0                  0
                                                  wk +MTX       10                  0                             NA                         0                            NA               0                        0                                                        0                  0
                                                  MTX                                                                                                                                                                                                                                           
  Westhovens et al. (23) Infliximab               3 mg/Kg 8     360                 18                            \_                         \_                                            6                                                                                 2                  0
                                                  wk +MTX       361                 20                            \_                         \_                                            18                                                                                2                  2
                                                  10 mg/Kg 8    721                 38                            512                        55                                            24                                                                                4                  2
                                                  wk +MTX       363                 8                             239                        27                           NA               6                        NA                                                       1                  1
                                                  Total                                                                                                                                                                                                                                         
                                                  Infliximab                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  Moreland et al. (24) Etanercept                 25 mg twice   78                  2                                                                                                      0                                                 \_                              0                  0
                                                  weekly        76                  5                                                                                                      0                                                 \_                              0                  0
                                                  10 mg twice   154                 7                                                                                                      0                                                 71                              0                  0
                                                  weekly        80                  3                             NA                         NA                           NA               0                                                 10                              0                  0
                                                  Total                                                                                                                                                                                                                                         
                                                  Etanercept                                                                                                                                                                                                                                    
                                                  Placebo                                                                                                                                                                                                                                       
  Weinblatt et al. (25) Etanercept                25 mg twice   59                  2                                                                                     30               0                                                 23                              0                  0
                                                  weekly        30                  1                             NA                         NA                           19               0                                                 2                               0                  0
                                                  +MTX MTX                                                                                                                                                                                                                                      
  Bathon et al. (26) Etanercept                   25 mg twice   207                 11                                                                                                                                                       \_                              3                  1
                                                  weekly        208                 12                                                                                                                                                       \_                              2                  1
                                                  10 mg twice   415                 23                                                                                                                                                       140                             5                  2
                                                  weekly        217                 24                            NA                         NA                           NA               NA                                                16                              2                  0
                                                  Total                                                                                                                                                                                                                                         
                                                  Etanercept                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  van der Heijde et al. (28) (TEMPO) Etanercept   25 mg twice   231                 37                            \_                         \_                           \_               23                                                                                5                  1
                                                  weekly        223                 34                            \_                         \_                           \_               24                                                                                5                  1
                                                  +MTX          454                 71                            379                        64                           285              47                                                69                              10                 2
                                                  25 mg twice   228                 47                            185                        37                           147              25                                                4                               2                  1
                                                  weekly                                                                                                                                                                                                                                        
                                                  Total                                                                                                                                                                                                                                         
                                                  Etanercept                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  Weinblatt et al. (29) (ARMADA) Adalimumab       40 mg/2 wk    67                  0                                                                                                      \_                                                \_                              \_                 \_
                                                  +MTX          69                  4                                                                                                      \_                                                \_                              \_                 \_
                                                  20 mg/2 wk    73                  1                                                                                                      \_                                                \_                              \_                 \_
                                                  +MTX          209                 5                                                                                                      2                                                 32                              1                  0
                                                  80 mg/2 wk    62                  2                             NA                         NA                           NA               0                                                 2                               0                  0
                                                  +MTX                                                                                                                                                                                                                                          
                                                  Total                                                                                                                                                                                                                                         
                                                  Adalimumab                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  van de Putte et al. (30) Adalimumab             40 mg/2 wk    113                 7                             \_                         \_                                            \_                                                \_                              \_                 1
                                                  20 mg/2 wk    106                 4                             \_                         \_                                            \_                                                \_                              \_                 0
                                                  20 mg/wk      112                 3                             \_                         \_                                            \_                                                \_                              \_                 0
                                                  40 mg/wk      103                 3                                                                                                                                                                                                           0
                                                  Total         434                 17                            429                        53                                            10                                                46                              4                  3
                                                  Adalimumab    110                 2                             105                        16                           NA               0                                                 1                               1                  1
                                                  Placebo                                                                                                                                                                                                                                       
  Furst et al. (31) (STAR) Adalimumab             40 mg/2 wk    318                 9                             275                        17                           166              4                                                 62                              1                  1
                                                  DMARD         318                 8                             275                        22                           157              6                                                 37                              0                  1
  Keystone y cols. (32) Adalimumab                40 mg/2 wk    207                 26                            \_                         \_                           \_               11                                                \_                              \_                 2
                                                  +MTX\*        212                 16                            \_                         \_                           \_               5                                                 \_                              \_                 1
                                                  20 mg/wk      419                 42                            391                        97                           269              16                                                101                             4                  3
                                                  +MTX          200                 13                            181                        37                           111              1                                                 48                              0                  0
                                                  Total                                                                                                                                                                                                                                         
                                                  Adalimumab                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           
  Breedveld et al. (33) (PREMIER) Adalimumab      40 mg/2 wk    268                 32                            \_                                                                       9                                                                                 2                  1
                                                  +MTX\*        274                 26                            \_                                                                       3                                                                                 4                  4
                                                  40 mg/2 wk    542                 58                            524                                                                      12                                                                                6                  5
                                                  Total         257                 19                            245                        NA                           NA               7                                                 NA                              4                  1
                                                  Adalimumab                                                                                                                                                                                                                                    
                                                  MTX                                                                                                                                                                                                                                           

NA: not available

\* Overall data provided although specific data per arm not provided

Regarding withdrawals due to adverse events, we found no significant overall difference between the experimental and control groups, with a pooled RR of 1.25 (0.65--2.39) (Figure [9](#F9){ref-type="fig"}). Results differed depending on the specific anti-TNFα given: patients in the etanercept arms were less likely to withdraw from adverse events than their control counterparts, but the opposite was the case for adalimumab and infliximab, all those comparisons reaching statistical significance. There was statistically significant heterogeneity among the drugs (Q = 29.3; p = 0.003; I^2^59) but not within the groups given each specific drug. The results were the same when only groups receiving recommended doses of anti-TNFα drugs were studied. Higher than recommended doses of infliximab led to a higher withdrawal rates. There were no significant differences in withdrawal rates between lower than recommended dose and control arms.

![Adverse event withdrawn in patients with all doses of anti-TNFα drugs.](1471-2474-9-52-9){#F9}

There were more adverse events in patients allocated to anti-TNFα drugs (RR 1.02 (1.00--1.04)) (p = 0.021) (Table [6](#T6){ref-type="table"}). Patients receiving infliximab showed a higher frequency of serious adverse events (p = 0.048) and infections (p = 0.004), but the combined estimates for all three anti-TNFα drugs and safety outcomes were not significant.

###### 

Adverse events in patients being treated with anti-TNFα drugs versus control

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ADVERSE EVENTS (anti TNFα vs. control) (references)           Anti-TNFα    Anti-TNFα Adverse events/total   Controls Adverse events/total   RR (95%CI)       NNH(95%CI)        Q        I^2^%
  ------------------------------------------------------------- ------------ -------------------------------- ------------------------------- ---------------- ----------------- -------- -------
  Withdrawn adverse event                                       Adalimumab   131/1922                         44/947                          1.4(1.0--2.0)    47(26--251)       1.2      0

  (4826 vs. 2261)                                               Etanercept   103/1082                         75/555                          0.7(0.5--0.9)    -26(-143 a -14)   2.4      0

  \*\* (19,20,22,23,24,25,26,28,29,30,31,32,33)                 Infliximab   134/1822                         24/759                          2.0(1.3--3.1)    24(17--41)        4.9      0

                                                                Total        368/4826                         143/2261                        1.3(0.7--2.4)    NS                29.3\*   59

  Total adverse events (3228 vs. 1564) (19,23,28,30,31,32,33)   Adalimumab   1619/1713                        806/885                         1.1(0.9--1.1)    NS                1.9      0

  (3228 vs. 1564)                                               Etanercept   379/454                          185/228                         1.0(0.9--1.1)    NS                0        0

  (19,23,28,30,31,32,33)                                        Infliximab   835/1061                         322/45                          1.0(0.9--1.0)    NS                1.6      39

                                                                Total        2833/3228                        1313/1564                       1.0(1.0--1.5)    27(17--59)        2.9      0

  Serious adverse events                                        Adalimumab   167/1171                         75/628                          1.0(0.7--1.4)    NS                2.6      25

  (3235 vs. 1615)                                               Etanercept   64/454                           37/228                          0.9(0.5--1.6)    NS                0        0

  (19,20,22,23,28,30,31,32)                                     Infliximab   217/1610                         77/759                          1.4(1.0--2.0)    31(17--167)       6.2      52

                                                                Total        448/3235                         189/1615                        1.1(0.8--1.6)    NS                14.3\*   51

  Infections                                                    Adalimumab   435/737                          268/518                         1.1(0.9--1.2)    NS                0.7      0

  (2341 vs. 1162)                                               Etanercept   315/513                          166/258                         1.0(0.9--1.0)    NS                0.9      0

  (19,20,25,28,31,32,33)                                        Infliximab   658/1091                         194/386                         1.2(1.1--1.3)    10(7--24)         0.03     0

                                                                Total        1408/2341                        628/1162                        1.9(0.9--1.2)    NS                8.6      41

  Serious infections                                            Adalimumab   44/1922                          14/947                          1.2(0.6--2.8)    NS                5.8      31

  (4188 vs.1937)                                                Etanercept   47/454                           25/28                           0.9(0.4--2.3)    NS                0        0

  (19,20,22,23,24,25,28,29,30,31,32,33)                         Infliximab   90/1812                          19/726                          1.8(0.9--3.4)    NS                2.7      26

                                                                Total        181/4188                         58/1937                         1.4(0.8--2.2)    NS                11.8     32

  Infusión reactions\                                           Infliximab   136/761                          20/308                          2.7(1.7--4.2)    9(7--14)          0.005    0
  (761 vs. 308)\                                                                                                                                                                          
  (20,22)                                                                                                                                                                                 

  Injection-site reactions                                      Adalimumab   241/1380                         88/690                          1.7(1.0--3.0)    22(13--67)        12.6\*   72

  (2454 vs. 1245)                                               Etanercept   303/1074                         32/555                          5.1(2.9--8.8)    5(4--6)           2.3      0

  (24,25,26,28,29,30,31,32)                                     Total        544/2454                         120/1245                        3.0(1.0--8.6)    8(7--10)          51.8\*   86

  Malignancies                                                  Adalimumab   16/1922                          5/947                           1.1(0.4--2.7)    NS                1.6      0

  (4826 vs. 2261)                                               Etanercept   15/1082                          4/555                           1.9(0.6--5.7)    NS                0.3      0

  (19,20,22,23,24,25,26,28,29,30,31,32,33)                      Infliximab   13/1822                          1/759                           2.6(0.6--11.6)   NS                1.1      0

                                                                Total        44/4826                          10/2261                         1.5(0.8--3.0)    NS                3.3      0

  Mortality                                                     Adalimumab   10/1922                          3/947                           1.3(0.4--4.7)    NS                2.0      0

  (4826 vs. 2261)                                               Etanercept   4/1082                           1/555                           1.5(0.2--9.5)    NS                0.2      0

  (19,20,22,23,24,25,26,28,29,30,31,32,33)                      Infliximab   9/1822                           5/759                           0.5(0.2--1.4)    NS                0.4      0

                                                                Total        23/4826                          9/2261                          0.8(0.3--2.1)    NS                4.4      0
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RR (95%CI): relative risk (95% confidence limits)

NNH: number needed to harm

Q: Cochrane\'s Q

I^2^: percentage of variability in study results attributable to between-study differences

\* statistical heterogeneity

NS: non-significant results

\*\* this figure include 208 patients of the Bathon trial not included in efficacy studies as efficacy date were not reported

Information on severe infections, malignancies and deaths was provided in all trials except for severe infections in the Bathon trial. No significant combined increases in risk were seen for any of these results.

We also inquired whether higher than recommended doses are associated with higher incidences of adverse events. The reported data were incomplete, however, as the Lipsky et al. trial \[[@B19]\] did not assign the 22 severe infections detected to each corresponding infliximab dose arm. The risk of severe infection when receiving high doses of infliximab \[[@B20],[@B23]\] was significantly increased (p = 0.006) with an NNH of 40 (26--91), but the risk of developing malignancies was not increased (p = 0.116). Nor did the two trials \[[@B29],[@B30]\] administering high doses of adalimumab report the dose received by patients experiencing severe infections.

Discussion
==========

This study approached a problem of major clinical and socio-economic importance: the efficacy and safety of anti-TNFα drugs in the treatment of rheumatoid arthritis (RA). We have considered these drugs both individually and as a specific therapeutic group. We have evaluated their efficacy as monotherapy and in combination with MTX. In addition, the efficacies of different doses and the safety of these drugs were explored.

Our search of the literature on the efficacy of anti-TNFα drugs in RA identified thirteen clinical trials fulfilling the required criteria for inclusion in the systematic review and metaanalysis. All thirteen were randomised-controlled trials with a minimal follow-up time of 6 months and used comparable standardised parameters of efficacy. Although the general quality of the trials was high, some difficulties became apparent during the review. The number of trials fulfilling the required criteria was small. Furthermore, there were several sources of clinically relevant heterogeneity: different control treatments were used, populations were not homogeneous, follow-up times differed among trials and the doses administered varied widely (Table [1](#T1){ref-type="table"}). Also, the funnel plot asymmetry might indicate publication bias or other types of problems.

In our study, combined analysis of the results from all trials using the recommended doses led us to conclude that anti-TNFα drugs (considered as a therapeutic group) show an effect significantly superior to that of control treatments. However, the heterogeneity was very high, calling for subgroups and more homogeneous comparisons. We only evaluated those trials for which relevant homogeneous comparisons were possible, and a substantial reduction in heterogeneity was apparent when we focused on these groups (Table [4](#T4){ref-type="table"}). Comparison of the three anti-TNFα drug plus MTX with MTX alone in patients with insufficient responses to MTX showed no significant heterogeneity of effects, yet despite the absence of head to head comparisons we found no evidence whatsoever that the relative effects of individual drugs are different. Etanercept seemed superior to adalimumab when both drugs were compared to placebo. However, the response observed in the control group of the adalimumab study was substantially higher than that of the etanercept reference group, which casts doubts on the actual comparability of the results and makes it difficult to draw definitive conclusions until the drugs have been compared directly in well designed, head to head randomised trials. Anti-TNFα drug plus MTX had a greater effect than MTX alone in patients with no previous resistance to MTX, but the magnitude of this effect was markedly lower than that obtained in patients with previously inadequate responses to MTX. Trials that assessed this specific efficacy issue recruited patients with short-lasting, less severe disease showing high responses to both experimental and control treatments, thus explaining the lower relative and absolute efficacy estimates (Table [4](#T4){ref-type="table"}). In fact, the effects achieved with etanercept and adalimumab in these patients were equivalent to those obtained using MTX for the first time.

When the potential influence on efficacy of doses administered was evaluated, both higher and lower doses than are currently recommended seemed to elicit similar effects, except for the effect of lower doses on ACR70. However, comparisons in this last case are based on a small number of patients.

In the light of these findings it seems sensible to advise that current treatment of moderate and severe RA should be started with MTX. Anti-TNFα drugs should be restricted to patients who do not respond sufficiently to DMARD combinations until experimental evidence demonstrates that the new biological drugs have greater efficacy in earlier stages of RA. It might also be potentially useful to start the indicated treatment with a low dose and then increase it as a function of the magnitude of the response. An alternative option might be to start with the current recommended doses and try to decrease them after a significant stable effect is reached, in order to minimise adverse effects. This issue encompasses important clinical and economic implications probably meriting further research.

For a correct interpretation of our results, the fact that our analyses were based on the ACR response should be taken into account. In recent years, another multidimensional index, the DAS index, has been increasingly used \[[@B65]\]. However, it was not used in any of the trials included in the current review. ACR20, 50 and 70 responses are well-known validated response criteria and they were available in all these anti-TNFα studies, enabling us to conduct a combined analysis and statistical evaluation of the results. Another important subject in the evaluation of the response of RA to anti-TNFα drugs is the quantification of radiological damage (inhibition of progression of structural joint damage). The modified Sharp score was analysed in six trials providing 12-month results and showing the ability of infliximab, etanercept and adalimumab to inhibit the progression of structural joint damage in RA \[[@B19],[@B20],[@B26],[@B28],[@B32],[@B33]\]. Nevertheless, several factors deterred us from using this score as an outcome variable: since it is not normally distributed, the way this index was summarised and displayed in the identified trials did not permit statistical pooling of the results. Moreover the clinical implications of this radiological finding are not yet well understood.

Safety issues are also of central concern. Although we focused solely on published results from well-designed randomised controlled trials, our review shows that patients receiving anti-TNFα drugs are more prone to experience adverse events. Although some of the relative safety estimates are statistically significant, their magnitude is rather small and their clinical relevance should be also addressed. Patients on infliximab and adalimumab withdrew from the trial because of adverse events more frequently than patients on etanercept. Treatment with infliximab is associated with higher frequencies of serious adverse events and infections. If high doses are administered, there is also an increased likelihood of severe infections. All in all, the safety/efficacy relationship as estimated by the NNH/NNT ratio appears to be favourable.

Two metaanalysis have been performed previously \[[@B66],[@B67]\] focusing the problem, although none has been published. Both showed a greater efficacy of etanercept against infliximab. A comprehensive technical report addressing these issues, including an economic evaluation, has recently been published by Chen et al. \[[@B68]\]. Although the deadline for inclusion of studies was February 2005, that article pooled information from 29 studies as its inclusion criteria were much broader: it included studies of shorter duration \[[@B46],[@B43],[@B46]-[@B48],[@B44]\], studies using other than the recommended routes of administration \[[@B49],[@B51],[@B52]\], studies in which no arm received recommended doses \[[@B62]\] and a trial in which efficacy was not measured using ACR criteria \[[@B58]\]. It also included unpublished studies. Despite this less restrictive approach, the Chen et al. paper likewise confirms the efficacy of all three marketed anti-TNFα drugs at recommended doses, especially when administered to patients with previous resistance to MTX.

A metaanalysis recently published by Bongartz et al. \[[@B7]\] focused on safety matters regarding infliximab and adalimumab. The risk of malignancies and infections was increased when higher doses were administered. There have been some controversies surrounding its conclusions, involving the accuracy of clinical trials with short follow-up as a means of detecting severe adverse events \[[@B69]\]. With respect to severe infections, our metaanalysis, although it detected a higher frequency in the anti-TNFα arms, showed no significant difference. We pooled safety data from the three available treatments whereas Bongartz et al. \[[@B7]\] only analysed infliximab and adalimumab using a fixed effects pooling method. If we restrict our analysis to infliximab and adalimumab and use a fixed effects model, we also find a significantly higher frequency of severe infections (p = 0.047) with an NNH of 61 (41--126). Therefore, it is likely that the use of both drugs, especially in higher than recommended doses, may increase the risk of severe infections. This risk has not so far been shown for etanercept, but as far as we are aware no study with higher than recommended doses has been published. Our results regarding the incidence of malignancies do not agree with those of Bongartz et al. \[[@B7]\], but they also include malignancies developed at a later stage when the trials are no longer underway.

Recently, two systematic reviews with meta-analysis have been published addressing the role of anti-TNFα drugs as added to MTX vs. MTX alone \[[@B70],[@B71]\]. Both articles select a very limited number of trials, and share an important design limitation, namely, they compare clinical trials that recruit both MTX-naïve patients and MTX-resistant patients, which, from our standpoint leads to their results facing validity problems.

There are limitations to our study that are also shared by other published metaanalyses \[[@B7],[@B68]\] and deserve further comment. The number of published studies is scarce, there is significant heterogeneity in some relevant aspects (patient clinical profiles, comparisons undertaken and lengths of follow-up) and information on safety parameters varies widely among trials. We have attempted to deal with these limitations in the original research by designing and applying rather stringent selection criteria so that our results are based on solid coherent evidence. This reinforcement of internal validity might have been at the expense of some loss of generalizability, yet the quality of information excluded is at least controversial. We have provided these pooled NNTs as a kind of effect estimate for average risk patients. In an attempt to minimise the presence of factors known to influence risks and therefore NNTs, we have selected rather homogeneous studies in terms of minimum follow-up, diagnostic criteria and have further made subgroup analyses accounting for several important clinical characteristics. We have performed an extensive and detailed analysis of available efficacy and safety data.

Conclusion
==========

It may be concluded that the three marketed anti-TNFα drugs are more effective than the corresponding control treatments (MTX or placebo) in RA patients, with an NNT of 5 for ACR20 and ACR50 and of 7 for ACR70 at currently recommended doses (Table [3](#T3){ref-type="table"}). High heterogeneity among trials is apparent in key design aspects and is reflected in the results of the combined analysis of all trials, calling for more in-depth assessment of more homogeneous subgroups. When this task is addressed, patients with previously inadequate responses to MTX show similar positive responses when any of the anti-TNFα drugs are added to their treatment regimes. However, when anti-TNFα drug plus MTX is compared with MTX alone in patients with no previous resistance to MTX, the relative efficacy of the combined regime is much lower. Etanercept and adalimumab are superior to the placebo but their effect in monotherapy is similar to that obtained with MTX. Therefore, we advise against starting treatment with anti-TNFα drugs until a lack of adequate response to MTX is clearly documented. Increasing doses lead to no increase in efficacy (Table [3](#T3){ref-type="table"}). Analysis of the effect of low anti-TNFα doses suggests that patients treated with etanercept or adalimumab might obtain clinically substantial benefits with doses lower than those currently recommended if indicated on the basis of safety or other grounds.

Overall, patients on anti-TNFα drugs experience adverse events more frequently and those using infliximab and adalimumab have higher withdrawal rates. Infliximab use is associated with a higher likelihood of severe adverse events including severe infections. Interestingly, though, patients using etanercept seem to do so with lower frequency, although this finding might be due to the limitation of the range of doses used to those recommended by the manufacturer. We found no significant difference in the development of malignancies during the follow-up times in the studies. The safety/efficacy relationship is favourable, especially if recommended doses are used. The safety profile of etanercept might be apparently superior because the other drugs were tested over a wider range of doses, including higher than recommended ones.

Although more research is warranted, especially well-powered head to head randomised comparisons of anti-TNFα drugs, our study helps to clarify some frequently encountered questions in the clinical care of RA patients.

Competing interests
===================

The author(s) declare that they have no competing interests.

Authors\' contributions
=======================

AA-R conceived and designed the study and was involved in data extraction, analysis and preparation of the manuscript. JIP was involved in statistical analysis and preparation of the manuscript. EA developed and conducted the search strategy. MC contributed to data extraction, AU to statistical analysis and AQ to analysis and preparing of the manuscript. All authors critically revised the manuscript and approved it for publication. AA-R is the guarantor.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2474/9/52/prepub>
